Frontiers in medicine · 2025
Visual outcomes with two posterior chamber phakic intraocular lenses in myopic patients: a contralateral eye study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Boliang, Chen Xun, Cheng Mingrui, Lin I-Chun, Jiang Yinjie, Lei Yadi, Xu Guanghan, Li Mingwei, Mao Zhiwei, Zhou Xingtao, Wang Xiaoying
Аннотация
PURPOSE: Assess the efficacy, safety, and visual quality of two posterior chamber phakic intraocular lenses (PIOL) for myopia correction.
METHODS: In this randomized double-blind prospective controlled trial, 38 eyes of 19 myopic patients received phakic refractive (PR) IOL in one eye and implantable collamer lens (EVO ICL) in the opposite eye and were followed up for 1 year. Uncorrected distance visual acuity, corrected distance visual acuity, vault, disk halo size, contrast sensitivity, higher-order aberrations, retinal imaging quality, intraocular scattering, and subjective glare/halo perception were measured.
RESULTS: At 1 year, mean efficacy indices were 1.03 ± 0.16 (PR) and 1.01 ± 0.15 (ICL), and mean safety indices were 1.18 ± 0.07 (PR) and 1.15 ± 0.09 (ICL). The PR group had lower vaults than those of the ICL group at 1 year (342.63 ± 153.94 vs. 470.00 ± 230.31 μm, P = 0.010). One month postoperatively, the severity of glare/halo was significantly milder in the PR group than that in the ICL group (P = 0.035). However, 1 year postoperatively, no significant differences were observed in the severity of glare/halo between the two groups.
CONCLUSION: Phakic refractive implantation is a safe and effective treatment option for myopia. The PR group exhibited lower vaults than those of the ICL group. The PR group had milder glare/halo in the early postoperative period compared to the ICL group, though long-term differences were not significant.
METHODS: In this randomized double-blind prospective controlled trial, 38 eyes of 19 myopic patients received phakic refractive (PR) IOL in one eye and implantable collamer lens (EVO ICL) in the opposite eye and were followed up for 1 year. Uncorrected distance visual acuity, corrected distance visual acuity, vault, disk halo size, contrast sensitivity, higher-order aberrations, retinal imaging quality, intraocular scattering, and subjective glare/halo perception were measured.
RESULTS: At 1 year, mean efficacy indices were 1.03 ± 0.16 (PR) and 1.01 ± 0.15 (ICL), and mean safety indices were 1.18 ± 0.07 (PR) and 1.15 ± 0.09 (ICL). The PR group had lower vaults than those of the ICL group at 1 year (342.63 ± 153.94 vs. 470.00 ± 230.31 μm, P = 0.010). One month postoperatively, the severity of glare/halo was significantly milder in the PR group than that in the ICL group (P = 0.035). However, 1 year postoperatively, no significant differences were observed in the severity of glare/halo between the two groups.
CONCLUSION: Phakic refractive implantation is a safe and effective treatment option for myopia. The PR group exhibited lower vaults than those of the ICL group. The PR group had milder glare/halo in the early postoperative period compared to the ICL group, though long-term differences were not significant.